FDA Grants RMAT Designation to Orca Bio's Orca-Q for High-Risk Hematologic Malignancies
Orca Bio, a biotechnology company based in Menlo Park, California, has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational therapy, Orca-Q. This designation is based on promising preliminary data from a Phase 1 clinical trial, which showed positive outcomes in overall survival, acute and chronic graft versus host disease (GVHD), and non-relapse mortality. The trial, which has been expanded to include additional patient cohorts, is evaluating Orca-Q for the treatment of high-risk hematologic malignancies. Orca-Q is a second-generation allogeneic T-cell immunotherapy developed using Orca Bio's high-precision platform. The RMAT designation is intended to accelerate the development and review of promising therapies for serious or life-threatening conditions. 
